Chong Xu, PhD, is a Partner at F-Prime Capital, an early-stage healthcare venture firm part of Fidelity Investments. See sector focus and contact routes.
Chong Xu, PhD, is a Partner at F-Prime Capital, an early-stage healthcare venture firm part of Fidelity Investments, where he joined in 2015 after roles at McKinsey and as a healthcare equity analyst. He focuses primarily on biopharmaceutical and medical technology sectors, supporting early-stage companies in Seed, Series A, and Series B rounds across the U.S., Europe, China, India, and Japan. Xu typically acts as a founding investor or board member, with F-Prime’s check sizes for his opportunities ranging from $100,000 to $10 million and averaging around $5 million. Notable portfolio companies include Aiolos Bio (acquired by GSK for up to $1.4 billion), OnCusp Therapeutics (which raised $100M Series A with Xu joining its board), AlphaGen Tx, and Skyline Therapeutics. He leverages his PhD in Cell Biology to evaluate novel scientific approaches and works closely with Eight Roads Ventures Asia on China-related investments. Xu has not published distinctive public writing or a unique stated point of view beyond his focus on breakthrough healthcare solutions and scientific founder collaboration.
This profile is part of the StartupFundraising investor database: focus, portfolio history, disclosed location and contact routes, refreshed as new filings and rounds are ingested. Founders use it to check fit before reaching out and to find investors in Boston.
Investors like Chong Xu · Full investor directory · Investor access · Company funding database